Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity. This story matters for Finance & Markets readers tracking largecap. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LargecapNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily largecap signal